Pan-resistant HIV-1 emergence in the INSTI era: a case study

Pan-resistant HIV-1 emergence in the INSTI era: a case study

Online publication: 11/06/2020 Printed publication: 11 June 2020


In 2019, WHO reported that the prevalence of HIV-1 drug resistance to first-line regimens of non-nucleoside reverse transcriptase inhibitors is increasing in countries with a low number of therapeutic options. This increasing prevalence of drug resistance is an important threat to ending the AIDS pandemic, as it compromises individual clinical outcomes and increases the risk of transmission. In countries with a high number of therapeutic options, little global information is available regarding the prevalence of multidrug-resistant HIV-1 infections, which presents a potential challenge for the clinical management of people with HIV. Even after the approval of two new antiretroviral drug classes in 2007, which were intended to help alleviate this problem, some cases of infection with HIV-1 that show limited susceptibility to the five available antiretroviral classes have been described. We did a thorough in-vitro evaluation of the drug resistance profile of HIV-1 from an observational case to show that five-class pan-resistant clinical cases do exist.

Authors: Puertas MC, Ploumidis G; Ploumidis M, Fumero E, Clotet B, Walworth CM, Petropoulos CJ, Martinez-Picado J

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut


HR Excellence in Research

Member of:


In cooperation with: